CD274 and breast cancer: The authors examined the effect of recombinant high-mobility group box 1 (rHMB1) through receptors for advanced glycation end products (RAGE) on cell migration in human breast cancer cell lines, concluding that after down-regulating AKT, the subsequent PI3K inhibition dephosphorylated AKT, and prevented PD-L1 expression [159].